- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare DSP Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.91 | 1.93 |
NAV | ₹39.95 | ₹37.84 |
Fund Started | 12 Nov 2018 | 25 Jun 2018 |
Fund Size | ₹3339.79 Cr | ₹5320.29 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.91
1.93
NAV
₹39.95
₹37.84
Fund Started
12 Nov 2018
25 Jun 2018
Fund Size
₹3339.79 Cr
₹5320.29 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 24.92% | 27.84% |
3 Year | 22.15% | 24.39% |
5 Year | 27.01% | 28.02% |
1 Year
24.92%
27.84%
3 Year
22.15%
24.39%
5 Year
27.01%
28.02%
Holding Analysis
Equity | 96.87% | 98.07% |
Cash | 3.13% | 1.93% |
Equity
96.87%
98.07%
Cash
3.13%
1.93%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.59% |
Suven Pharmaceuticals Ltd. | 8.49% |
Cipla Ltd. | 8.20% |
Ipca Laboratories Ltd. | 8.14% |
Globus Medical Inc | 5.70% |
Illumina Inc. (USA) | 4.78% |
Alembic Pharmaceuticals Ltd. | 4.54% |
Gland Pharma Ltd. | 4.38% |
Apollo Hospitals Enterprise Ltd. | 4.07% |
Concord Biotech Ltd. | 3.87% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.83% |
Cipla Ltd. | 9.28% |
Dr. Reddy's Laboratories Ltd. | 8.93% |
Divi's Laboratories Ltd. | 5.56% |
Aurobindo Pharma Ltd. | 5.05% |
Lupin Ltd. | 4.67% |
Alkem Laboratories Ltd. | 3.98% |
Gland Pharma Ltd. | 3.73% |
Mankind Pharma Ltd. | 3.22% |
Zydus Lifesciences Ltd. | 2.96% |
Fund Manager
Name | Jay Kothari | Dharmesh Kakkad |
Start Date | 16 Mar 2018 | 23 Feb 2021 |
Name
Jay Kothari
Dharmesh Kakkad
Start Date
16 Mar 2018
23 Feb 2021
About Fund
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 12 Nov 2018 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
12 Nov 2018
25 Jun 2018
